Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1682 1693
This examiner grants 36% of resolved cases
Amanda Marie Haney is an examiner in Art Unit 1634 within Tech Center 1600. The examiner has 719 resolved cases and an allowance rate of 36.4 percent. This allowance rate is relatively low, suggesting that applicants may face a rigorous examination process in this biotechnology or organic chemistry area. The 719 resolved cases provide a substantial dataset for understanding the examiner's approach to patentability.
The median time to allowance for these cases is 1275 days. This figure indicates a lengthy prosecution timeline, which practitioners should factor into their overall strategy. The 1275-day duration represents the typical path for applications that successfully overcome rejections. Managing client expectations around this 1275-day benchmark is essential for those navigating the 1600 Tech Center and Art Unit 1634.
The data shows a significant interview lift of 44.8 percent. This suggests that conducting an interview is a highly effective way to improve the odds of success, potentially moving an application from the baseline toward a grant. The 44.8 percent lift is a critical metric for this examiner, indicating that direct communication is a vital tool for resolving outstanding issues. Practitioners should prioritize scheduling a formal discussion to navigate the challenges reflected in the 36.4 percent allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17612610 | PROTOCOL FOR DETECTING INTERACTIONS WITHIN ONE OR MORE DNA MOLECULES WITHIN A CELL | Non-Final OA | Oxford Nanopore Technologies PLC |
| 17416510 | Optimizing Detection of Transplant Injury by Donor-Derived Cell-Free DNA | Non-Final OA | The Regents of the University of California |
| 17047006 | NON-INVASIVE DETECTION OF RESPONSE TO IMMUNOTHERAPY | Final Rejection | The Johns Hopkins University |
| 16809496 | METHOD OF IDENTIFYING RISK FOR AUTISM | Final Rejection | The Johns Hopkins University |
| 18422276 | METHOD AND SYSTEM FOR RISK ASSESSMENT OF AUTISM SPECTRUM DISORDER IN A SUBJECT | Non-Final OA | Tata Consultancy Services Limited |
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | Final Rejection | The Medical College of Wisconsin, Inc. |
| 16623725 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | Final Rejection | The Medical College of Wisconsin, Inc. |
| 18548972 | ISOTHERMAL AMPLIFICATION OF PATHOGENS | Non-Final OA | BECTON, DICKINSON AND COMPANY |
| 18548865 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17353279 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | Non-Final OA | Myriad Genetics, Inc. |
| 17787499 | PRIMERS FOR DETECTING TRACE AMOUNT OF RARE SINGLE- NUCLEOTIDE VARIANT AND METHOD FOR SPECIFICALLY AND SENSITIVELY DETECTING TRACE AMOUNT OF RARE SINGLE-NUCLEOTIDE VARIANT BY USING SAME | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18251654 | CIRCULATING miRNA AND PROTEIN BIOMARKERS FOR FACIOSCAPULOHUMERAL DYSTROPHY | Non-Final OA | CHILDREN'S NATIONAL MEDICAL CENTER |
| 17905129 | METHODS OF USING A MULTI-ANALYTE APPROACH FOR DIAGNOSIS AND STAGING A DISEASE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18038915 | METHOD FOR DETECTING SEVERITY OF ATOPIC DERMATITIS | Final Rejection | KAO CORPORATION |
| 17904348 | NUCLEIC ACID PROBES | Non-Final OA | Agency for Science, Technology and Research |
| 17196631 | METHODS AND COMPOSITIONS FOR DETECTION OF HPV DNA AND DIAGNOSIS AND MONITORING OF HPV-ASSOCIATED CANCERS | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18353647 | COMPOSITIONS AND METHODS FOR CHARACTERIZING ZDHHC1 DNA | Non-Final OA | Exact Sciences Corporation |
| 18557446 | METHODS FOR MEASURING POLY A TAIL LENGTH | Final Rejection | TRANSLATE BIO, INC. |
| 18560569 | NOVEL PREDICTIVE BIOMARKERS FOR SECONDARY AUTOIMMUNITY AFTER LYMPHOCYTE DEPLETING THERAPY | Non-Final OA | GENZYME CORPORATION |
| 18176152 | TESTING ASSAY FOR SCREENING AND DIAGNOSIS OF USHER, PENDRED, JERVELL, AND LANGE-NIELSEN SYNDROMES | Non-Final OA | Father Flanagan's Boys' Home Doing Business as Boys Town National Research Hospital |
| 17251359 | PREDICTIVE 7-GENE ASSAY AND PROGNOSTIC PROTEIN BIOMARKER FOR NON-SMALL CELL LUNG CANCER | Final Rejection | West Virginia University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy